Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06175845 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma

Study acronym: ACTICCA-2
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 5 months later Jan 2026 → Jul 2027
See other at-risk trials from Universitätsklinikum Hamburg-Eppendorf

Record History

  1. Primary completion pushed from Jan 2026 to Jul 2027v2 Show 4 more changesShow less
    • Start date changed from estimate of Feb 2024 to Aug 30, 2024
    • Trial status changed: Unknown → Recruiting
    • Trial sites expanded: 1 → 9 locations
    • Study completion pushed from Jul 2026 to Nov 2027
  2. Changed Registry marked status Unknown; last known: Not Yet Recruiting
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting. The main questions it aims to answer are: * Does radiofrequency ablation of tumorous bile duct occlusion reduce risk of complications in these patients (eg stent dysfunction, delay of chemotherapy, infections etc)? * Is radiofrequency ablation safe in these patients? All participants will receive standard treatment with systemic chemotherapy and bile duct stenting. Researchers will compare two groups (one group will receive additional radiofrequency ablation, the other not).
Trial Details
NCT Number NCT06175845
Lead Sponsor Universitätsklinikum Hamburg-Eppendorf
Conditions
(from sponsor)		 Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
Related terms Bile Duct Neoplasms, Bites and Stings, Cholangiocarcinoma, Cholangitis, Klatskin Tumor, Liver Neoplasms
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov